Cubist Pharma Cvr (CBSTZ) 0.06 $CBSTZ
Third Rock Ventures Names Industry Leader Michael W. Bonney as Partner
BusinessWire - Thu Jan 07, 11:05AM CST
Third Rock Ventures, LLC today announced that Michael W. Bonney is joining the firm as a partner effective today. Most recently, Mr. Bonney served as chief executive officer of Cubist Pharmaceuticals Inc. (a subsidiary of Merck & Co., Inc. as of January 2015) from June 2003 until December 2014. His prior experience includes leadership positions in successful biotechnology and pharmaceutical companies such as Biogen and Zeneca Pharmaceuticals (now AstraZeneca). He also holds several board positions in leading biotechnology companies.
CBSTZ: 0.06 (unch), MRK: 62.98 (+0.08)
Alnylam Announces Updates to Company's Board of Directors Supportive of Transition Towards Commercial Stage
BusinessWire - Fri Dec 18, 3:00PM CST
--- David Pyott, Former Allergan Chairman and CEO, Elected to Board -
AGN: 235.96 (-1.80), CBSTZ: 0.06 (unch), ALNY: 69.17 (+0.15)
Rhythm Appoints David Meeker, MD, and David McGirr to Board of Directors
PR Newswire - Wed Dec 16, 7:00AM CST
Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic metabolic disorders, announced today that the company has appointed David Meeker, MD, and David McGirr to its Board of Directors. Dr. Meeker is President and Chief Executive Officer of Genzyme, and Mr. McGirr is former Chief Financial Officer of Cubist Pharmaceuticals.
CBSTZ: 0.06 (unch)
Acacia Pharma: Dr Patrick Vink to Succeed Ian Kent as Non-Executive Chairman
PR Newswire - Thu Dec 03, 3:00AM CST
Acacia Pharma Group plc ("Acacia Pharma"
, the supportive care company developing products for US and international markets, today announces that Ian Kent will retire as non-executive Chairman on 31st December 2015 and will be succeeded by Dr Patrick Vink.
CBSTZ: 0.06 (unch)
Global Non-Invasive Cancer Diagnostics Market, 2015 - 2030
M2 - Fri Nov 06, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/l59gmq/noninvasive) has announced the addition of the "Non-Invasive Cancer Diagnostics Market, 2015 - 2030" report to their offering. The Non-Invasive Cancer Diagnostics Market Is Anticipated to Grow Aggressively at a Healthy Annual Growth Rate of 44% Between 2015 and 2030 Cancer is an extremely complex disease and medical science is still struggling to figure out the reasons and factors influencing the disease origin, propagation, spread (metastasis) and relapse. In addition to satisfying the unmet market need for advanced and efficient treatment interventions, cancer prevention, early detection and management is extremely important. The high cancer mortality rate is primarily due to delay in detection of the disease. Early diagnosis and screening makes it possible to cure the disease completely and/or increase survival rates. Over the years, various technological advances have helped medical professionals understand cancer better. Recent research in cancer biology has led to a lot of innovation in the development of a number of new diagnostic tools. These modern diagnostic techniques can help detect and classify cancer with increased accuracy and sensitivity. It is also important to highlight that the cost of management and treatment of cancer is a growing concern considering its highly progressive and fatal nature. Performing a biopsy includes costs associated with the equipment, cost of the procedure itself, consultation fees, hospital fees, costs of analytical tests and those associated with post-operative care. To manage this financial burden, the introduction of novel non-invasive techniques, which are cost-effective and more accurate, has become an indispensable necessity. There are several advanced approaches, which are non-invasive or minimally invasive in nature, and these outweigh the limitations posed by invasive diagnostic procedures. Specifically, liquid biopsy has emerged as a promising non-invasive cancer diagnostic tool for early detection as well as monitoring the disease's progress. This technique of tracing the presence of circulating biomarkers in blood and other biological fluids of cancer patients is becoming increasingly popular in the medical fraternity.In addition to liquid biopsy, the market is gradually witnessing the emergence of several other non-invasive diagnostic technologies. These include techniques based on molecular imaging, advanced genomic and transcriptomic methods of detection of clinically significant biomarkers and identification of nucleosomal levels. All such non-invasive tests hold a significant promise to enhance the quality of patient care. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Concept Of Non-Invasive Cancer Screening And Diagnostics 5. Market Overview 6. Liquid Biopsy: Detailed Outlook 7. Other Novel Non-Invasive Technologies 8. Market Sizing And Forecast 9. Company Profiles Companies Mentioned - Partial List of the 150 Companies Featured - A&G Pharmaceutical - Accelerate Brain Cancer Cure - America's Choice Provider Network - Cubist Pharmaceuticals - CynvenioBiosystems - Epigenomics - European Medical Network for Translational Research in Ovarian Cancer - Exact Sciences - Exosome Diagnostics - Exosomics Siena - Fairview Health Services - FedMed - Flatiron Health - Fluxion Biosciences - Incyte Genomics - Inivata - Insight Genetics - MolecularMD - Molecular Pathology Laboratory Network - Natera - National Cancer Institute - NeoGenomics Laboratory - Novartis - Novigenix - Ortho Biotech Oncology Research & Development - Pacific Edge - Palex Medical - Pathway Genomics - PathQC - Personal Genome Diagnostics - Promega Corporation - Prostate Cancer Foundation - Qiagen - Quanterix - RainDance Technologies For more information visit http://www.researchandmarkets.com/research/l5...oninvasive
CBSTZ: 0.06 (unch), NVS: 79.38 (+1.11)
CoLucid Pharmaceuticals Announces Election of Mark Corrigan, M.D., to Board of Directors
GlobeNewswire - Tue Oct 27, 7:00AM CDT
CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches in adults, announced today that Mark Corrigan M.D., has been elected by the Board of Directors to serve as a director. Dr. Corrigan is filling a seat created by the resignation of Richard Markham, and will serve as a class II director of the Company with a term expiring at the annual meeting of stockholders to be held in 2017. In addition, Dr. Corrigan has been elected as Chairman of the Compensation Committee. CoLucid's Board remains at seven directors, six of whom are independent.
CBSTZ: 0.06 (unch), CLCD: 10.66 (+0.41), MRK: 62.98 (+0.08), EPRS: 0.14 (-0.01)
GNS Healthcare Strengthens Foothold in Clinical Care Management, Appoints Nationally Regarded Authorities to Strategic Advisory Board
BusinessWire - Mon Sep 28, 7:05AM CDT
GNS Healthcare (GNS), a leading provider of analytics solutions for driving personalized interventions that improve population health, today announced the expansion of its Strategic Advisory Board (SAB). Joining the SAB are Susan Weaver, MD, former Chief Medical Officer of Blue Cross and Blue Shield of North Carolina; Robert J. Perez, the former Chief Executive Officer of Cubist Pharmaceuticals, Inc., acquired by Merck (NASDAQ: MRK) for $9.5 Billion in January 2015; Steve Eisenberg, MD, former Vice President, Healthcare Informatics for UnitedHealth Group (NYSE:UNH) subsidiary OptumHealth; and Timothy Thompson, Chairman and CEO of Intervention Insights.
CBSTZ: 0.06 (unch), UNH: 136.61 (+0.87), MRK: 62.98 (+0.08), AET: 116.73 (+0.57)
Zafgen Announces Transition of Board of Directors
GlobeNewswire - Mon Sep 28, 6:00AM CDT
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced the appointment of Robert Perez and Geoffrey McDonough, M.D., to its Board of Directors.
ZFGN: 2.95 (-0.09), CBSTZ: 0.06 (unch)
Spero Expands Leadership Team, Advisory Board with Industry Veterans
BusinessWire - Thu Sep 17, 7:15AM CDT
Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, announced the appointment of John Tomayko, M.D., as Chief Medical Officer. Dr. Tomayko, who is board certified in internal medicine and infectious disease, brings more than 20 years of experience in the development of innovative antibacterial compounds to the pioneering efforts at Spero, in addition to expertise in the rational design of clinical development pathways. Other recent additions to the Spero team include, Scott Coleman, Ph.D., as Head of Nonclinical Development and Tim Keutzer as Vice President of Development. Milind S. Deshpande, Ph.D., President and Chief Executive Officer of Achillion, who has served on the Spero Board of Directors since inception, has been elevated to the position of Chairman of the Board. He succeeds Jean Francois Formela of Atlas Venture, Spero's founding investor, as Chair.
CBSTZ: 0.06 (unch)
Rob Perez Joins Flex Pharma's Board of Directors
BusinessWire - Tue Sep 08, 8:47AM CDT
Click to Tweet this News
CBSTZ: 0.06 (unch), AMAG: 23.66 (-0.05), FLKS: 11.15 (-0.11)
Analyzing the Global Biotechnology Industry 2015 - The Medical/Healthcare Segment is the Leading Segment of the Biotechnology Industry Consisting of nearly 60%
M2 - Tue Aug 18, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6ddnn/analyzing_the) has announced the addition of the "Analyzing the Global Biotechnology Industry 2015" report to their offering. Biotechnology as an industry has been around for many years now. The manipulation of biological processes is nothing new as the fermenting of grains and fruits to create alcoholic beverages to the discovery of penicillin has been around since the 1920s. Advances in genomics, molecular biology and computing power has made it possible for the field of biotechnology to advance and develop more targeted medicines, manufacture high nutrition crops, and even manufacture grow artificial organs and tissues. Emerging markets like China, Brazil and India are leading the sales in the global biotechnology market. The Americas and Europe regions hold the biggest share in the global biotechnology industry - Americas had a share of nearly 45%, followed by Europe accounting for nearly 30% of the global biotechnology industry. The medical/healthcare segment is the leading segment of the biotechnology industry and in 2014 it consisted of nearly 60% of the global biotech industry's total value. This was followed by the food and agriculture segment. The research analyzes the Global Biotechnology Industry in this comprehensive research report. Analyzing the Global Biotechnology Industry covers the biotech market from the year 2010 till 2019. The report analyzes a total of 23 biotech markets and over 40 biotech companies. Key Topics Covered: A. Executive Summary B. Industry Definition C. Global Biotechnology Industry D. Global Biotechnology Industry: Porter's Five Forces Framework Analysis E. Blurring Differences between Biotech & Pharma Companies F. Global Biotechnology Industry: Market Trends & Challenges G. Global Biotechnology Industry: Analysis of Key Markets H. Global Biotechnology Industry: Major Players Companies Mentioned - AbbVie Inc. - Abbott Laboratories - Acorda Therapeutics Inc. - Actelion Ltd - Amgen, Inc. - Amylin Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Baxter International Inc. - Biocon Limited - Biogen Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CSL Limited - Celgene Corporation - Covance Inc. - Crucell N.V. - Cubist Pharmaceuticals - Daiichi Sankyo Co., Ltd. - Esteve Group - F. Hoffmann-La Roche AG - GE Healthcare - Gentium S.p.A. - Genzyme Corporation - Gilead Sciences, Inc. - Grifols SA - ImmunoGen, Inc. - Johnson & Johnson - Menarini Group - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - MorphoSys AG - Novartis AG For more information visit http://www.researchandmarkets.com/research/r6...lyzing_the
ACOR: 24.27 (-0.07), CVD: 106.42 (-0.71), JNJ: 119.32 (+0.24), ABBV: 64.12 (+0.09), ABT: 42.09 (-0.21), CBSTZ: 0.06 (unch), IMGN: 2.75 (-0.05), AMGN: 169.77 (-0.36), BMY: 56.35 (-0.41), GRFS: 16.04 (+0.14), GILD: 76.89 (-0.53), BAX: 46.28 (+0.10), AZN: 33.31 (+0.71), MRK: 62.98 (+0.08), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05)
Global Bacterial Endocarditis active pharmaceutical ingredients (API) Insights Report 2015-2016
M2 - Mon Aug 17, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xrsc27/bacterial) has announced the addition of the "Bacterial Endocarditis-API Insights" report to their offering. Bacterial Endocarditis-API Insights, 2015 report provides Bacterial Endocarditis drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Bacterial Endocarditis. The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Bacterial Endocarditis drugs till 2016. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China. Companies Mentioned - Cubist Pharmaceuticals, Inc. - Lilly USA, LLC - Hospira, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Pfizer Inc. - Baxter Healthcare Corporation - B. Braun Medical Inc. - Bristol-Myers Squibb Company - Abbott Laboratories - LNK International Inc. - Paddock Laboratories, Inc. For more information visit http://www.researchandmarkets.com/research/xrsc27/bacterial
ABT: 42.09 (-0.21), CBSTZ: 0.06 (unch), PFE: 34.77 (+0.09), LLY: 76.85 (-0.38), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41)
marcus evans to Host the 3rd Pharma Data Analytics Conference in Philadelphia
Marketwire Canada - Thu Aug 13, 12:14PM CDT
marcus evans, the world's largest event management group, will host the 3rd Annual Pharma Data Analytics Conference on November 18-19, 2015 in Philadelphia, PA. Building on the success of last year's event, attendees will gain a comprehensive understanding of the challenges key pharmaceutical leaders working in data analytics and information technology are currently facing.
JNJ: 119.32 (+0.24), CBSTZ: 0.06 (unch), PFE: 34.77 (+0.09), MRK: 62.98 (+0.08), ILMN: 167.90 (-0.66), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), ALKS: 45.12 (+0.38), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05)
PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team
PR Newswire Europe - Tue May 26, 1:00AM CDT
PureTech, a science-driven healthcare company seeking to solve some of today's toughest health challenges in disruptive ways, announced today that Dame Marjorie Scardino, Chairman of the MacArthur Foundation and former CEO of Pearson, has been appointed to PureTech's Board of Directors in the role of Senior Independent Director and that current Board member Joi Ito, MIT Media Lab's Director, has been appointed Board Chairman. Dr. Ben Shapiro, PureTech's outgoing Chairman and co-founder, former Executive Vice President of Basic & External Research at Merck, will remain an active member of the Board.
CBSTZ: 0.06 (unch), MRK: 62.98 (+0.08)
Synereca Pharmaceuticals Appoints Dr. Mark Corrigan to Its Board of Directors
PR Newswire - Wed May 20, 7:00AM CDT
Synereca Pharmaceuticals, Inc. (SPI), a research-stage biopharmaceutical company developing compounds that restore or increase the effectiveness of existing antibiotics against serious Gram-Negative infections, announced today the appointment of Mark H. N. Corrigan, M.D., to the Company's Board of Directors. Dr. Corrigan is a seasoned life sciences executive with broad operational and clinical development experience at leading pharmaceutical and biotechnology companies.
CBSTZ: 0.06 (unch), MRK: 62.98 (+0.08)
Inhibikase Therapeutics, Inc. Elects Richard Fante And Patrick Vink To Its Board Of Directors
PR Newswire - Mon May 04, 9:00AM CDT
Inhibikase Therapeutics, Inc. announces the election of Richard Fante, former President of AstraZeneca U.S.A. and CEO of AstraZeneca North America and the election of Patrick Vink, former Executive Vice President and COO of Cubist Pharmaceuticals, to its Board of Directors. Anthony Zook has stepped down from the Board due to his new role as CEO of Innocoll AG.
CBSTZ: 0.06 (unch)
Major Big Biotech Deals and Alliances of 2014
M2 - Thu Apr 30, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v2r4fv/big_biotech_deals) has announced the addition of the "Big Biotech Deals and Alliances of 2014" report to their offering. A review of big biotech partnering trends and comprehensive directory of deals and alliances announced during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report provide an orientation of 2014's dealmaking and business activities. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2014. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2014. Key Topics Covered: Chapter 1 - Trends in dealmaking during 2014 1.1. Big biotech dealmaking activity 1.2. Partnering by deal type 1.3. Partnering by industry sector 1.4. Partnering by stage of development 1.5. Partnering by technology type 1.6. Partnering by therapy area Chapter 2 - Leading deals during 2014 2.1. Introduction 2.2. Top deals by value during 2012 Chapter 3 - Big biotech deals during 2014 3.1. Introduction 3.2. How to use big biotech partnering deals 3.3. Big biotech partnering company profiles for 2014 - Roche - Teva Pharmaceuticals - Amgen - Novo Nordisk - Merck KGaA - Gilead Sciences - Actavis - Biogen Idec - Celgene - Allergan - Valeant Pharmaceuticals - CSL - Shire - UCB - Grifols - Endo International - Sun Pharmaceutical - Regeneron Pharmaceuticals - Actelion - Ipsen - Alexion Pharmaceuticals - Vertex Pharmaceuticals - United Therapeutics - Cubist Pharmaceuticals - Salix Pharmaceuticals - Jazz Pharmaceuticals - Questcor Pharmaceuticals - The Medicines Company - LFB Group - Alkermes Chapter 4 - Partnering deals directory 2014 4.1. Introduction 4.2. Company A-Z 4.3. By deal type 4.4. By stage of development 4.5. By technology type 4.6. By therapy area For more information visit http://www.researchandmarkets.com/research/v2...tech_deals
BIIB: 313.59 (+7.56), VRTX: 95.11 (+0.36), CBSTZ: 0.06 (unch), UTHR: 122.91 (-0.30), SLXP: 172.96 (+0.15), AMGN: 169.77 (-0.36), ALKS: 45.12 (+0.38), AGN: 235.96 (-1.80), NVO: 45.80 (-0.54), GILD: 76.89 (-0.53), JAZZ: 120.84 (-2.47), ALXN: 123.67 (-1.96), REGN: 388.64 (-4.76), CELGZ: 1.18 (+0.05)
Yumanity Therapeutics Appoints Paulash Mohsen to Chief Business Officer
BusinessWire - Wed Apr 29, 7:00AM CDT
Yumanity Therapeutics, a company focused on transforming drug discovery for diseases caused by protein misfolding, today announced the appointment of Paulash Mohsen as chief business officer. Mr. Mohsen joins Yumanity from Cubist Pharmaceuticals and brings more than 18 years of operational, commercial and business development experience in the biotech and pharmaceutical industries.
CBSTZ: 0.06 (unch)
Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA(TM) (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases
BusinessWire - Mon Apr 27, 5:30PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that The Lancet and Clinical Infectious Diseases have published online the results from the pivotal Phase 3 clinical studies of ZERBAXA(TM) (ceftolozane/tazobactam) for Injection (1 g/0.5 g) in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), respectively. The results will also appear in forthcoming print issues of the journals. Merck acquired ZERBAXA as a part of its purchase of Cubist Pharmaceuticals, Inc.
CBSTZ: 0.06 (unch), MRK: 62.98 (+0.08)
Third Rock Ventures Names Industry Leader Michael W. Bonney as Partner
BusinessWire - Thu Jan 07, 11:05AM CST
Third Rock Ventures, LLC today announced that Michael W. Bonney is joining the firm as a partner effective today. Most recently, Mr. Bonney served as chief executive officer of Cubist Pharmaceuticals Inc. (a subsidiary of Merck & Co., Inc. as of January 2015) from June 2003 until December 2014. His prior experience includes leadership positions in successful biotechnology and pharmaceutical companies such as Biogen and Zeneca Pharmaceuticals (now AstraZeneca). He also holds several board positions in leading biotechnology companies.
CBSTZ: 0.06 (unch), MRK: 62.98 (+0.08)
Alnylam Announces Updates to Company's Board of Directors Supportive of Transition Towards Commercial Stage
BusinessWire - Fri Dec 18, 3:00PM CST
--- David Pyott, Former Allergan Chairman and CEO, Elected to Board -
AGN: 235.96 (-1.80), CBSTZ: 0.06 (unch), ALNY: 69.17 (+0.15)
Rhythm Appoints David Meeker, MD, and David McGirr to Board of Directors
PR Newswire - Wed Dec 16, 7:00AM CST
Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic metabolic disorders, announced today that the company has appointed David Meeker, MD, and David McGirr to its Board of Directors. Dr. Meeker is President and Chief Executive Officer of Genzyme, and Mr. McGirr is former Chief Financial Officer of Cubist Pharmaceuticals.
CBSTZ: 0.06 (unch)
Acacia Pharma: Dr Patrick Vink to Succeed Ian Kent as Non-Executive Chairman
PR Newswire - Thu Dec 03, 3:00AM CST
Acacia Pharma Group plc ("Acacia Pharma"
, the supportive care company developing products for US and international markets, today announces that Ian Kent will retire as non-executive Chairman on 31st December 2015 and will be succeeded by Dr Patrick Vink. CBSTZ: 0.06 (unch)
Global Non-Invasive Cancer Diagnostics Market, 2015 - 2030
M2 - Fri Nov 06, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/l59gmq/noninvasive) has announced the addition of the "Non-Invasive Cancer Diagnostics Market, 2015 - 2030" report to their offering. The Non-Invasive Cancer Diagnostics Market Is Anticipated to Grow Aggressively at a Healthy Annual Growth Rate of 44% Between 2015 and 2030 Cancer is an extremely complex disease and medical science is still struggling to figure out the reasons and factors influencing the disease origin, propagation, spread (metastasis) and relapse. In addition to satisfying the unmet market need for advanced and efficient treatment interventions, cancer prevention, early detection and management is extremely important. The high cancer mortality rate is primarily due to delay in detection of the disease. Early diagnosis and screening makes it possible to cure the disease completely and/or increase survival rates. Over the years, various technological advances have helped medical professionals understand cancer better. Recent research in cancer biology has led to a lot of innovation in the development of a number of new diagnostic tools. These modern diagnostic techniques can help detect and classify cancer with increased accuracy and sensitivity. It is also important to highlight that the cost of management and treatment of cancer is a growing concern considering its highly progressive and fatal nature. Performing a biopsy includes costs associated with the equipment, cost of the procedure itself, consultation fees, hospital fees, costs of analytical tests and those associated with post-operative care. To manage this financial burden, the introduction of novel non-invasive techniques, which are cost-effective and more accurate, has become an indispensable necessity. There are several advanced approaches, which are non-invasive or minimally invasive in nature, and these outweigh the limitations posed by invasive diagnostic procedures. Specifically, liquid biopsy has emerged as a promising non-invasive cancer diagnostic tool for early detection as well as monitoring the disease's progress. This technique of tracing the presence of circulating biomarkers in blood and other biological fluids of cancer patients is becoming increasingly popular in the medical fraternity.In addition to liquid biopsy, the market is gradually witnessing the emergence of several other non-invasive diagnostic technologies. These include techniques based on molecular imaging, advanced genomic and transcriptomic methods of detection of clinically significant biomarkers and identification of nucleosomal levels. All such non-invasive tests hold a significant promise to enhance the quality of patient care. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Concept Of Non-Invasive Cancer Screening And Diagnostics 5. Market Overview 6. Liquid Biopsy: Detailed Outlook 7. Other Novel Non-Invasive Technologies 8. Market Sizing And Forecast 9. Company Profiles Companies Mentioned - Partial List of the 150 Companies Featured - A&G Pharmaceutical - Accelerate Brain Cancer Cure - America's Choice Provider Network - Cubist Pharmaceuticals - CynvenioBiosystems - Epigenomics - European Medical Network for Translational Research in Ovarian Cancer - Exact Sciences - Exosome Diagnostics - Exosomics Siena - Fairview Health Services - FedMed - Flatiron Health - Fluxion Biosciences - Incyte Genomics - Inivata - Insight Genetics - MolecularMD - Molecular Pathology Laboratory Network - Natera - National Cancer Institute - NeoGenomics Laboratory - Novartis - Novigenix - Ortho Biotech Oncology Research & Development - Pacific Edge - Palex Medical - Pathway Genomics - PathQC - Personal Genome Diagnostics - Promega Corporation - Prostate Cancer Foundation - Qiagen - Quanterix - RainDance Technologies For more information visit http://www.researchandmarkets.com/research/l5...oninvasive
CBSTZ: 0.06 (unch), NVS: 79.38 (+1.11)
CoLucid Pharmaceuticals Announces Election of Mark Corrigan, M.D., to Board of Directors
GlobeNewswire - Tue Oct 27, 7:00AM CDT
CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches in adults, announced today that Mark Corrigan M.D., has been elected by the Board of Directors to serve as a director. Dr. Corrigan is filling a seat created by the resignation of Richard Markham, and will serve as a class II director of the Company with a term expiring at the annual meeting of stockholders to be held in 2017. In addition, Dr. Corrigan has been elected as Chairman of the Compensation Committee. CoLucid's Board remains at seven directors, six of whom are independent.
CBSTZ: 0.06 (unch), CLCD: 10.66 (+0.41), MRK: 62.98 (+0.08), EPRS: 0.14 (-0.01)
GNS Healthcare Strengthens Foothold in Clinical Care Management, Appoints Nationally Regarded Authorities to Strategic Advisory Board
BusinessWire - Mon Sep 28, 7:05AM CDT
GNS Healthcare (GNS), a leading provider of analytics solutions for driving personalized interventions that improve population health, today announced the expansion of its Strategic Advisory Board (SAB). Joining the SAB are Susan Weaver, MD, former Chief Medical Officer of Blue Cross and Blue Shield of North Carolina; Robert J. Perez, the former Chief Executive Officer of Cubist Pharmaceuticals, Inc., acquired by Merck (NASDAQ: MRK) for $9.5 Billion in January 2015; Steve Eisenberg, MD, former Vice President, Healthcare Informatics for UnitedHealth Group (NYSE:UNH) subsidiary OptumHealth; and Timothy Thompson, Chairman and CEO of Intervention Insights.
CBSTZ: 0.06 (unch), UNH: 136.61 (+0.87), MRK: 62.98 (+0.08), AET: 116.73 (+0.57)
Zafgen Announces Transition of Board of Directors
GlobeNewswire - Mon Sep 28, 6:00AM CDT
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced the appointment of Robert Perez and Geoffrey McDonough, M.D., to its Board of Directors.
ZFGN: 2.95 (-0.09), CBSTZ: 0.06 (unch)
Spero Expands Leadership Team, Advisory Board with Industry Veterans
BusinessWire - Thu Sep 17, 7:15AM CDT
Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, announced the appointment of John Tomayko, M.D., as Chief Medical Officer. Dr. Tomayko, who is board certified in internal medicine and infectious disease, brings more than 20 years of experience in the development of innovative antibacterial compounds to the pioneering efforts at Spero, in addition to expertise in the rational design of clinical development pathways. Other recent additions to the Spero team include, Scott Coleman, Ph.D., as Head of Nonclinical Development and Tim Keutzer as Vice President of Development. Milind S. Deshpande, Ph.D., President and Chief Executive Officer of Achillion, who has served on the Spero Board of Directors since inception, has been elevated to the position of Chairman of the Board. He succeeds Jean Francois Formela of Atlas Venture, Spero's founding investor, as Chair.
CBSTZ: 0.06 (unch)
Rob Perez Joins Flex Pharma's Board of Directors
BusinessWire - Tue Sep 08, 8:47AM CDT
Click to Tweet this News
CBSTZ: 0.06 (unch), AMAG: 23.66 (-0.05), FLKS: 11.15 (-0.11)
Analyzing the Global Biotechnology Industry 2015 - The Medical/Healthcare Segment is the Leading Segment of the Biotechnology Industry Consisting of nearly 60%
M2 - Tue Aug 18, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6ddnn/analyzing_the) has announced the addition of the "Analyzing the Global Biotechnology Industry 2015" report to their offering. Biotechnology as an industry has been around for many years now. The manipulation of biological processes is nothing new as the fermenting of grains and fruits to create alcoholic beverages to the discovery of penicillin has been around since the 1920s. Advances in genomics, molecular biology and computing power has made it possible for the field of biotechnology to advance and develop more targeted medicines, manufacture high nutrition crops, and even manufacture grow artificial organs and tissues. Emerging markets like China, Brazil and India are leading the sales in the global biotechnology market. The Americas and Europe regions hold the biggest share in the global biotechnology industry - Americas had a share of nearly 45%, followed by Europe accounting for nearly 30% of the global biotechnology industry. The medical/healthcare segment is the leading segment of the biotechnology industry and in 2014 it consisted of nearly 60% of the global biotech industry's total value. This was followed by the food and agriculture segment. The research analyzes the Global Biotechnology Industry in this comprehensive research report. Analyzing the Global Biotechnology Industry covers the biotech market from the year 2010 till 2019. The report analyzes a total of 23 biotech markets and over 40 biotech companies. Key Topics Covered: A. Executive Summary B. Industry Definition C. Global Biotechnology Industry D. Global Biotechnology Industry: Porter's Five Forces Framework Analysis E. Blurring Differences between Biotech & Pharma Companies F. Global Biotechnology Industry: Market Trends & Challenges G. Global Biotechnology Industry: Analysis of Key Markets H. Global Biotechnology Industry: Major Players Companies Mentioned - AbbVie Inc. - Abbott Laboratories - Acorda Therapeutics Inc. - Actelion Ltd - Amgen, Inc. - Amylin Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Baxter International Inc. - Biocon Limited - Biogen Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CSL Limited - Celgene Corporation - Covance Inc. - Crucell N.V. - Cubist Pharmaceuticals - Daiichi Sankyo Co., Ltd. - Esteve Group - F. Hoffmann-La Roche AG - GE Healthcare - Gentium S.p.A. - Genzyme Corporation - Gilead Sciences, Inc. - Grifols SA - ImmunoGen, Inc. - Johnson & Johnson - Menarini Group - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - MorphoSys AG - Novartis AG For more information visit http://www.researchandmarkets.com/research/r6...lyzing_the
ACOR: 24.27 (-0.07), CVD: 106.42 (-0.71), JNJ: 119.32 (+0.24), ABBV: 64.12 (+0.09), ABT: 42.09 (-0.21), CBSTZ: 0.06 (unch), IMGN: 2.75 (-0.05), AMGN: 169.77 (-0.36), BMY: 56.35 (-0.41), GRFS: 16.04 (+0.14), GILD: 76.89 (-0.53), BAX: 46.28 (+0.10), AZN: 33.31 (+0.71), MRK: 62.98 (+0.08), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05)
Global Bacterial Endocarditis active pharmaceutical ingredients (API) Insights Report 2015-2016
M2 - Mon Aug 17, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xrsc27/bacterial) has announced the addition of the "Bacterial Endocarditis-API Insights" report to their offering. Bacterial Endocarditis-API Insights, 2015 report provides Bacterial Endocarditis drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Bacterial Endocarditis. The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Bacterial Endocarditis drugs till 2016. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China. Companies Mentioned - Cubist Pharmaceuticals, Inc. - Lilly USA, LLC - Hospira, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Pfizer Inc. - Baxter Healthcare Corporation - B. Braun Medical Inc. - Bristol-Myers Squibb Company - Abbott Laboratories - LNK International Inc. - Paddock Laboratories, Inc. For more information visit http://www.researchandmarkets.com/research/xrsc27/bacterial
ABT: 42.09 (-0.21), CBSTZ: 0.06 (unch), PFE: 34.77 (+0.09), LLY: 76.85 (-0.38), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41)
marcus evans to Host the 3rd Pharma Data Analytics Conference in Philadelphia
Marketwire Canada - Thu Aug 13, 12:14PM CDT
marcus evans, the world's largest event management group, will host the 3rd Annual Pharma Data Analytics Conference on November 18-19, 2015 in Philadelphia, PA. Building on the success of last year's event, attendees will gain a comprehensive understanding of the challenges key pharmaceutical leaders working in data analytics and information technology are currently facing.
JNJ: 119.32 (+0.24), CBSTZ: 0.06 (unch), PFE: 34.77 (+0.09), MRK: 62.98 (+0.08), ILMN: 167.90 (-0.66), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), ALKS: 45.12 (+0.38), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05)
PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team
PR Newswire Europe - Tue May 26, 1:00AM CDT
PureTech, a science-driven healthcare company seeking to solve some of today's toughest health challenges in disruptive ways, announced today that Dame Marjorie Scardino, Chairman of the MacArthur Foundation and former CEO of Pearson, has been appointed to PureTech's Board of Directors in the role of Senior Independent Director and that current Board member Joi Ito, MIT Media Lab's Director, has been appointed Board Chairman. Dr. Ben Shapiro, PureTech's outgoing Chairman and co-founder, former Executive Vice President of Basic & External Research at Merck, will remain an active member of the Board.
CBSTZ: 0.06 (unch), MRK: 62.98 (+0.08)
Synereca Pharmaceuticals Appoints Dr. Mark Corrigan to Its Board of Directors
PR Newswire - Wed May 20, 7:00AM CDT
Synereca Pharmaceuticals, Inc. (SPI), a research-stage biopharmaceutical company developing compounds that restore or increase the effectiveness of existing antibiotics against serious Gram-Negative infections, announced today the appointment of Mark H. N. Corrigan, M.D., to the Company's Board of Directors. Dr. Corrigan is a seasoned life sciences executive with broad operational and clinical development experience at leading pharmaceutical and biotechnology companies.
CBSTZ: 0.06 (unch), MRK: 62.98 (+0.08)
Inhibikase Therapeutics, Inc. Elects Richard Fante And Patrick Vink To Its Board Of Directors
PR Newswire - Mon May 04, 9:00AM CDT
Inhibikase Therapeutics, Inc. announces the election of Richard Fante, former President of AstraZeneca U.S.A. and CEO of AstraZeneca North America and the election of Patrick Vink, former Executive Vice President and COO of Cubist Pharmaceuticals, to its Board of Directors. Anthony Zook has stepped down from the Board due to his new role as CEO of Innocoll AG.
CBSTZ: 0.06 (unch)
Major Big Biotech Deals and Alliances of 2014
M2 - Thu Apr 30, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v2r4fv/big_biotech_deals) has announced the addition of the "Big Biotech Deals and Alliances of 2014" report to their offering. A review of big biotech partnering trends and comprehensive directory of deals and alliances announced during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report provide an orientation of 2014's dealmaking and business activities. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2014. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2014. Key Topics Covered: Chapter 1 - Trends in dealmaking during 2014 1.1. Big biotech dealmaking activity 1.2. Partnering by deal type 1.3. Partnering by industry sector 1.4. Partnering by stage of development 1.5. Partnering by technology type 1.6. Partnering by therapy area Chapter 2 - Leading deals during 2014 2.1. Introduction 2.2. Top deals by value during 2012 Chapter 3 - Big biotech deals during 2014 3.1. Introduction 3.2. How to use big biotech partnering deals 3.3. Big biotech partnering company profiles for 2014 - Roche - Teva Pharmaceuticals - Amgen - Novo Nordisk - Merck KGaA - Gilead Sciences - Actavis - Biogen Idec - Celgene - Allergan - Valeant Pharmaceuticals - CSL - Shire - UCB - Grifols - Endo International - Sun Pharmaceutical - Regeneron Pharmaceuticals - Actelion - Ipsen - Alexion Pharmaceuticals - Vertex Pharmaceuticals - United Therapeutics - Cubist Pharmaceuticals - Salix Pharmaceuticals - Jazz Pharmaceuticals - Questcor Pharmaceuticals - The Medicines Company - LFB Group - Alkermes Chapter 4 - Partnering deals directory 2014 4.1. Introduction 4.2. Company A-Z 4.3. By deal type 4.4. By stage of development 4.5. By technology type 4.6. By therapy area For more information visit http://www.researchandmarkets.com/research/v2...tech_deals
BIIB: 313.59 (+7.56), VRTX: 95.11 (+0.36), CBSTZ: 0.06 (unch), UTHR: 122.91 (-0.30), SLXP: 172.96 (+0.15), AMGN: 169.77 (-0.36), ALKS: 45.12 (+0.38), AGN: 235.96 (-1.80), NVO: 45.80 (-0.54), GILD: 76.89 (-0.53), JAZZ: 120.84 (-2.47), ALXN: 123.67 (-1.96), REGN: 388.64 (-4.76), CELGZ: 1.18 (+0.05)
Yumanity Therapeutics Appoints Paulash Mohsen to Chief Business Officer
BusinessWire - Wed Apr 29, 7:00AM CDT
Yumanity Therapeutics, a company focused on transforming drug discovery for diseases caused by protein misfolding, today announced the appointment of Paulash Mohsen as chief business officer. Mr. Mohsen joins Yumanity from Cubist Pharmaceuticals and brings more than 18 years of operational, commercial and business development experience in the biotech and pharmaceutical industries.
CBSTZ: 0.06 (unch)
Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA(TM) (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases
BusinessWire - Mon Apr 27, 5:30PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that The Lancet and Clinical Infectious Diseases have published online the results from the pivotal Phase 3 clinical studies of ZERBAXA(TM) (ceftolozane/tazobactam) for Injection (1 g/0.5 g) in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), respectively. The results will also appear in forthcoming print issues of the journals. Merck acquired ZERBAXA as a part of its purchase of Cubist Pharmaceuticals, Inc.
CBSTZ: 0.06 (unch), MRK: 62.98 (+0.08)
